Effects of denosumab and alendronate at the ultradistal radius in postmenopausal women with low bone mass
Ego Seeman(The University of Melbourne), José Zanchetta(Universidad del Salvador), Stéphanie Boutroy(Université Claude Bernard Lyon 1), Alice M.S. Cheung(Duke-NUS Medical School), Sara Boyd(University of Calgary), Ann E. Kearns(Mayo Clinic), T. Thomas, Elizabeth Shane(Columbia University Irving Medical Center), Deborah E. Sellmeyer(University of California, San Francisco), César E. Bogado(Universidad del Salvador), P.D. Delmas(UConn Health), Michelle Fan(National Cancer Centre Japan), Cesar Libanati(Amgen (United States)), S. Majumdar(University of California, San Francisco), D.A. Hanley(University of Calgary)
Cited by 1
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k